IRCT20220515054863N2尚未招募未知
Comparison of the efficacy of Ranolazine with placebo for reducing ventricular premature beats (VPBs) in patients with high burden of VPBs in holter monitoring
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 96
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 no limit（—）
- 性别
- All
入选标准
- •Minimum age of 18
- •PVC burden between 10 to 30 percent among whole beats
排除标准
- •Patients with Atrial Fibrillation (AF)
- •Patients diagnosed with ischemic ventricular tachycardia (VT)
- •Patients with a history of serious ventricular tachyarrhythmias in the past 4 weeks (e.g., sustained ventricular tachycardia and ventricular fibrillation)
- •Patients who have a QT interval higher than 550 milliseconds or consume medications that prolong the QT interval
- •Patients with a heart transplant
- •Patients undergoing dialysis
- •Patients with a creatinine clearance below 30 ml/min or a blood creatinine over 2.5 mg/dl
- •Patients with moderate to severe hepatic dysfunction
- •Patients receiving metformin with a dose extending 1000 mg Bid
- •Patients receiving simvastatin with a daily dose extending 20 mg
- •Patients receiving Dabigatran
- •Patients receiving a CYP3A4 inhibitor (Ketoconazole, Clarithromycin, Ritonavir, Diltiazem, Fluconazole, Erythromycin, Verapamil or grapefruit juice)
- •Patients with a history of Ranolazine consumption in the past two months
- •Patients who have previously discontinued Ranolazine due to side effects
- •Pregnant or breastfeeding patients, or patients planning for pregnancy during the study period
- •Patients without informed consent
研究者
相似试验
已完成
4 期
Safety and efficacy of conventional drugs on Non-alcoholic fatty liver diseaseCTRI/2019/06/019592Self
招募中
2 期
Evaluation of the effect of Ranolazine on patients with slow flow coronary arteriesIRCT20220516054874N6Mashhad University of Medical Sciences48
招募中
3 期
Ranolazine effects on angina pectoris in patients with coronary artery bridgeMyocardial bridge in coronary arteries.Malformation of coronary vesselsQ24.5IRCT20230801059005N2Shiraz University of Medical Sciences52
已完成
3 期
Efficacy of Ranolazine in reduction of blood sugar in type 2 diabetic patients with ischemic heart diseaseCondition 1: Diabetes mellitus. Condition 2: Stable angina.Type 2 diabetes mellitus with hyperosmolarityOther forms of angina pectorisIRCT20161026030511N3Samin Daroo Company60
招募中
Unknown
Comparative in vivo evaluation of 2 Ranolazine 1000 mg ER Tablet and Ranexa® 1000 mg ER Tablet formulations.Angina pectoris.Angina pectorisIRCT20180620040164N50Zist Arvand Pharme Ltd.24